Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 4, 1997, Pages 349-356

  Schrör, Karsten ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Aspirin resistance; Atherosclerosis; Cyclooxygenase isoforms; Platelets; Thromboxane A2

Indexed keywords

ACETYLSALICYLIC ACID;

BRAIN BLOOD FLOW; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 0030852046     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996108     Document Type: Review

References (74)

1. Mueller RL, S Scheidt: History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation 89:432-449, 1994.
2. Quick AJ: Salicylates and bleeding: The aspirin tolerance test. Am J Med Sci 252:265-269, 1967.
3. Breddin K: Wirkungen von Pharmaka auf die Plättchenaggregation. Verhandlungen der Dtsch Arbeitsgemeinschaft für Blutgerinnungsforschung, Wien, 14.-15.4.1967. Schattauer, Stuttgart, 1968, pp 90-93.
4. Weiss HJ, LM Aledort, S Kochawa: The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 47: 2169-2180, 1968.
5. O'Brien JR: Effects of salicylates on human platelets. Lancet 1:779-783, 1968.
6. Vane JR: Inhibition of prostaglandin biosynthesis as a mechanism of action of aspirin-like drugs. Nature New Biol 231:232-235, 1971.
7. Smith JB, AL Willis: Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol 231:235-237, 1971.
8. Roth GJ, N Stanford, PW Majerus: Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 72:3073-3076, 1975.
9. Funk CD, LB Funk, ME Kennedy, AS Pong, GA FitzGerald: Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression and gene chromosomal assignment. FASEB J 5:2304-2312, 1991.
10. ++ concentrations. Thromb Res 75:233-242, 1994.
11. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy - I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106, 1994.
12. Shimokawa T, WL Smith: Prostaglandin endoperoxide synthase: The aspirin acetylation region. J Biol Chem 267:12387-12392, 1992.
13. Shimokawa T, RJ Kulmacz, DL DeWitt, WL Smith: Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J Biol Chem 265:20073-20076, 1990.
14. 2-synthase. Nature 267:243-249, 1994.
15. 2 synthase. Nature (Struct Biol) 2:637-643, 1995.
16. Otto JC, WL Smith: Prostaglandin endoperoxide synthases-1 and -2. J Lipid Med 12:139-156, 1995.
17. Wu KK: Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol 33:179-207, 1995.
18. Mitchell JA, P Akarasereenont, C Thiemermann, RJ Flower, JR Vane: Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693-11697, 1993.
19. Roth GJ, PW Majerus: The mechanism of the effect of aspirin on human platelets. J Clin Invest 56:624-632, 1975.
20. Nitelius E, B Brantmark, B Fredholm, U Hedner, G Plym Forshell, E Wahlin-Boll, A Melander: Actions and interactions of acetylsalicylic acid, salicylic acid and diflunisal on platelet aggregation. Eur J Clin Pharmacol 27:165-168, 1984.
21. Higgs GA, JA Salmon, B Henderson, JR Vane: Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci USA 84:1417-1420, 1987.
22. Kopp E, S Ghosh: Inhibition of NF-MB by sodium salicylate and aspirin. Science 265:956-959, 1994.
23. Frantz B, EA O'Neill: The effect of sodium salicylate and aspirin on NF-MB. Science 270:2017-2019, 1995.
24. Bozza PT, JL Payne, SG Morham, R Langenbach, O Smithies, PF Weller: Leukocyte lipid body formation and eicosanoid generation: Cyclooxygenase-independent inhibition by aspirin. Proc Natl Acad Sci USA: 93:11091-11096, 1996.
25. 2. FEBS Lett 397:108-112, 1996.
26. Schrör K: Prostacyclin and atherosclerosis. In: Rubanyi GM, V Dzau (eds) The Endothelium in Clinical Practice: Source and Target of Novel Therapies. Dekker, New York, 1997, pp. 1-44.
27. Patrignani R, P Filabozzi, C Patrono: Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69:1366-1372, 1982.
28. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325:1137-1141, 1991.
29. 1,α excretion in healthy subjects. Thromb Res 45:355-361, 1987.
30. Huijgens PC, CAM van den Berg, C van der Meer, LMFM Imandt, MMAC Langenhuijsen: Dosage of acetylsalicylic acid for inhibition of platelet function. Scand J Haematol 25:76-80, 1980.
31. FitzGerald GA, JA Oates, JA Hawiger, RA Maas, LJ Roberts II, JA Lawson, AR Brash: Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71: 676-683, 1983.
32. Patrono C: Aspirin as an antiplatelet drug. N Engl J Med 330:1287-1294, 1994.
33. Steering Committee of the Physicians' Health Study Research Group: Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321:129-135, 1989.
34. FitzGerald GA, B Smith, AK Pedersen, AR Brash: Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 310:1065-1068, 1984.
35. Knapp HR, C Healy, J Lawson, GA FitzGerald: Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. Thromb Res 50:377-386, 1988.
36. Force T, R Milani, P Hibberd, R Lorenz, W Uedelhoven, A Leaf, PC Weber: Aspirin-induced decline in prostacyclin production in patients with coronary artery disease is due to decreased endoperoxide shift. Circulation 84:2286-2293, 1991.
37. Pomerantz KB, DP Hajjar: Eicosanoids in regulation of arterial smooth muscle cell phenotype, proliferative capacity, and cholesterol metabolism. Arteriosclerosis 9:413-429, 1989.
38. Rimarachin JA, JA Jacobson, P Szabo, J Maclouf, C Creminon, BB Weksler: Regulation of cyclooxygenase-2-expression in aortic smooth muscle cells. Arterioscler Thromb 14:1021-1031, 1994.
39. Walters TK, DC Mitchell, RFM Wood: Low-dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease. Br J Surg 80:1266-1268, 1993.
40. Gent M and CAPRIE Steering Committee: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339, 1996.
41. Barnett HJM, M Eliasziw. HE Meldrum: Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 332:238-248, 1995.
42. Barnett HJM, M Kaste, H Meldrum, M Eliasziw: Aspirin dose in stroke prevention. Beautiful hypotheses slain by ugly facts. Stroke 27:588-592, 1996.
43. Patrono C, GJ Roth: Aspirin in ischemic cerebrovascular disease: How strong is the case for a different dosing regimen? Stroke 27:756-760, 1996.
44. Einhäupl KM, F Masuhr: Acetylsalicylsäure in der Prävention zerebrovaskulärer Erkrankungen. In: Schrör K, HK Breddin (eds) Acetylsalicylsäure im kardiovaskulären System. Birkhäuser, Basel, 1996, pp 153-170.
45. 2 and prostacyclin. Stroke 23:1400-1403, 1992.
46. Tohgi H, H Takahashi, K Tamura: Antiplatelet medication in cerebrovascular disease: Potential sources of controversies and future strategies. Platelets 5:13-19, 1994.
47. Algra A, J van Gijn: Aspirin at any dose above 30 mg offers only modest protection after cerebral ischemia. J Neurol Neurosurg Psychiatry 60:107-199, 1996.
48. Wu KK: Platelet activation mechanisms and markers in arterial thrombosis. J Intern Med 239:17-34, 1996.
49. 2 biosynthesis in human disease. Fed Proc 46:154-158, 1987.
50. Vejar M, G Fragasso, D Hackett, DP Lipkin, A Maseri, GVR Born, G Ciabattoni, C Patrono: Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemostas 63:163-168, 1990.
51. Lewis HD, JW Davis, DG Archibald, WE Steinke, TC Smitherman, JE Doherty III, HW Schnaper, NM LeWinter, E Linares, JM Pouget, SC Sabharwal, E Chesler, H DeMots: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative study. N Engl J Med 309:396-403, 1983.
52. Hass WK, JD Easton, HP Adams, W Pryse-Phillips, BA Molony: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients - TASS, ticlopidine aspirin stroke study. N Engl J Med 321:501-507, 1989.
53. Helgason CM, KM Bolin, JA Hoff, SR Winkler, A Mangat, KL Tortorice, LD Brace: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25:2331-2336, 1994.
54. Helgason CM, KL Tortorice, SR Winkler, DW Penney, JJ Schuler, TJ McClelland, LD Brace: Aspirin response and failure in cerebral infarction. Stroke 24:345-350, 1993.
55. Rajagopalan S, LV McIntyre, ER Hall, KK Wu: The stimulation of arachidonic acid metabolism in human platelets by hydrodynamic forces. Biochim Biophys Acta 958:108-115, 1988.
56. Moake JL, NA Turner, NA Stathopoulos, L Nolasco, JD Hellums: Shear-induced platelet aggregation can be mediated by VWF released from platelets, as well as by exogenous large or unusually large VWF-multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 71:1366-1374, 1988.
57. Maalej N, JD Folts: Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries. Circulation 93:1201-1205, 1996.
58. Larsson PT, NH Wallen, P Hjemdahl: Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 89:1951-1957, 1994.
59. Braun M, J Kramann, H Strobach, K Schrör: Incomplete inhibition of platelet secretion by low-dose aspirin. Platelets 5:325-331, 1994.
60. Kessels H, S Beguin, H Andree, HC Hemker: Measurement of thrombin generation in whole blood - The effect of heparin and aspirin. Thromb Haemostas 72:78-83, 1994.
61. Pappas JM, JC Westengard, BS Bull: Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 118:801-804, 1994.
62. Benedek IH, AS Joshi, HJ Picniaszek, S-YP King, DM Kornhauser. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 35:1181-1186, 1995.
63. ISIS-2: Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 2:349-360, 1988.
64. Kelly JP, DW Kaufman, JM Jurgelon, J Sheehan, RS Koff, S Shapiro: Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348: 1413-1416, 1996.
65. Hoftiezer JW, GR Silvoso, M Burks, KJ Ivey. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet 2:609-612, 1980.
66. Lanza FL, GL Royer Jr, RS Nelson: Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 303:136-138, 1980.
67. Hawthorne AB, YR Mahida, AT Cole, CJ Hawkey: Aspirin-induced gastric mucosal damage: Prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 32:77-83, 1991.
68. (The) Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325:1261-1266, 1991.
69. (The) SALT Collaborative Group: Swedish Aspirin low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338:1345-1349, 1991.
70. European Stroke Prevention Study (ESPS-2) Working Group. Secondary stroke prevention: Aspirin/dipyridamole combination is superior to either agent alone and to placebo. Stroke 27:195 (Abst), 1996.
71. Schrör K: Antiplatelet drugs. A comparative review. Drugs 50:7-28, 1995.
72. Gawaz M, F-J Neumann, U Ott, A May, A Schömig: Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 94:279-285, 1996.
73. Goods CM, KF Al-Snaibi, MW Liu, JS Yadav, A Mathur, SP Jain, LS Dean, SS Iyer, JM Parks, GS Roubin: Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. Am J Cardiol 78:1042-1044, 1996.
74. 2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation 89: 588-595, 1994.